CNS Pharmaceuticals, Inc.
CNSP
$5.78
-$0.16-2.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 47.58% | 17.11% | -85.05% | -35.53% | 44.79% |
| Total Depreciation and Amortization | 484.21% | 90.00% | 42.86% | -22.22% | -18.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.69% | -97.03% | 373.51% | -14.35% | -65.38% |
| Change in Net Operating Assets | -439.79% | -89.91% | 174.62% | 134.27% | -400.42% |
| Cash from Operations | 23.86% | -52.32% | -40.36% | 59.32% | -64.84% |
| Capital Expenditure | 38.71% | 65.93% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 38.71% | 65.93% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 5.61% | -212.34% | 66.15% | -2.13% | -2.53% |
| Issuance of Common Stock | 4,035.38% | -0.16% | 62,612.50% | -99.98% | -50.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -4,173.33% | -- | -100.00% |
| Cash from Financing | 4,984.58% | -0.54% | 544.21% | -102.07% | -54.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 500.79% | -59.59% | -17.53% | -146.77% | -113.94% |